Skip to content
10-Q

Quarterly Report

Statera Biopharma, Inc.

0001437749-22-024497

← back to feed
Filed
Oct 21, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2022 · Sep 26, 2022 50.74M sh
Stock Repurchased Q1 2022 · Mar 31, 2022 $51.31K
Stock Repurchased Q1 2022 · Mar 31, 2021 $0
Capex Q1 2022 · Mar 31, 2022 $6.45K
Capex Q1 2022 · Mar 31, 2021 $4.69K
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$3.76M
Operating Cash Flow restated Q1 2022 · Mar 31, 2021 −$2.59M
Long Term Debt Q1 2022 · Mar 31, 2022 $0
Long Term Debt Q1 2022 · Dec 31, 2021 $10.63M
Short Term Investments Q1 2022 · Mar 31, 2022 $178.39K
Short Term Investments Q1 2022 · Dec 31, 2021 $134.6K
Cash And Equivalents Q1 2022 · Mar 31, 2022 $152.18K
Cash And Equivalents Q1 2022 · Dec 31, 2021 $1.84M
Stockholders Equity Q1 2022 · Mar 31, 2022 −$2.49M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$1.57M
Current Liabilities Q1 2022 · Mar 31, 2022 $15.07M
Current Liabilities Q1 2022 · Dec 31, 2021 $11.25M
Total Liabilities Q1 2022 · Mar 31, 2022 $15.94M
Total Liabilities Q1 2022 · Dec 31, 2021 $22.68M
Current Assets Q1 2022 · Mar 31, 2022 $1.44M
Current Assets Q1 2022 · Dec 31, 2021 $4.15M
Total Assets Q1 2022 · Mar 31, 2022 $13.51M
Total Assets Q1 2022 · Dec 31, 2021 $21.17M
Eps Basic Q1 2022 · Mar 31, 2022 −$0.20
Eps Basic Q1 2022 · Mar 31, 2021 −$0.22
Rd Expense Q1 2022 · Mar 31, 2022 $3.24M
Rd Expense restated Q1 2022 · Mar 31, 2021 $1.02M
Net Income Q1 2022 · Mar 31, 2022 −$7.76M
Net Income restated Q1 2022 · Mar 31, 2021 −$5.29M
Operating Income Q1 2022 · Mar 31, 2022 −$6.61M
Operating Income restated Q1 2022 · Mar 31, 2021 −$5.19M
Gross Profit Q1 2022 · Mar 31, 2022 $644.17K
Gross Profit Q1 2022 · Mar 31, 2021 $0
Cost Of Revenue Q1 2022 · Mar 31, 2022 $353.67K
Cost Of Revenue Q1 2022 · Mar 31, 2021 $0
Revenue Q1 2022 · Mar 31, 2022 $997.84K
Revenue Q1 2022 · Mar 31, 2021 $0